Senseonics Holdings Inc

Senseonics Holdings, Inc. is a medical technology company focused on the design, development, and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. Its flagship products, Eversense 365 and Eversense E3, feature a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor, continuously measuring glucose levels for up to 365 days and 180 days, respectively. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone. The company has brought its U.S. and European commercial operations fully in-house, transitioning from its prior distribution partner Ascensia, and operates the Eon Care nursing network to support sensor insertion procedures. Senseonics sells primarily in the United States and select European markets including Germany, Italy, Spain, and Sweden. The company is advancing its Gemini clinical program and Freedom development program as next-generation CGM platforms. Eversense 365 is also compatible with the twistä Automated Insulin Delivery system. Updated Aug 6, 2026